Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menstrual blood-derived stem cell ovarian injection for poor ovarian response
IRCT20180619040147N2Phase 2Completed
- Sponsor
- ACECR
- Start
- Aug 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous menstrual blood-derived stem cells in poor ovarian response (POR) (2 arms), sponsored by ACECR. Primary endpoints: Number of antral follicles, Anti-Mullerian hormone levels and 8 more. Started Aug 2018; status: completed.
02
Drugs
autologous menstrual blood-derived stem cells
03
Conditions
poor ovarian response (POR)
Beyond the preview
Go deeper on IRCT20180619040147N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180619040147N2.